Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis.

Slides:



Advertisements
Similar presentations
© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
Advertisements

Efficacy and Safety of Fondaparinux in Elderly Patients With ST-Segment Elevation Myocardial Infarction: Data From the OASIS 6 Trial Efficacy and Safety.
Clinical Trial Results. org Based on the Iron (Fe) and Atherosclerosis Study (FeAST) Leo R. Zacharski, MD; Bruce K. Chow, MS; Paula S. Howes, MS, APRN;
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
Primary PCI Treatment of choice for Acute MI.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
TRI vs TFI in STEMI Shenyang Northern Hospital Wang Shouli Han Yalin.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Comparing Hospital Performance in Door-to-Balloon Time Between the Hospital Quality Alliance and the National Cardiovascular Data Registry Brahmajee K.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Published in Circulation 2003 Rory Hachamovitch, MD, MSc; Sean W. Hayes, MD; John D. Friedman, MD; Ishac Cohen PhD; Daniel S. Berman, MD Comparison of.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
EXAMINATION Objective Assess the safety and performance of a new-generation DES vs. a BMS in the setting of primary PCI for treatment of patients with.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Prehospital ECGs for Acute Coronary Syndromes Summary and Comment by Aaron E. Bair, MD, MSc, FAAEM, FACEP Published in Journal Watch Emergency Medicine.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction STRATEGY Trial Journal of the American Medical.
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:
Risk of bolus thrombolytics Shamir Mehta, MD Director, Coronary Care Unit McMaster University Medical Center Hamilton, Ontario Paul Armstrong, MD Professor.
Effect of Rosiglitazone on the Risk of Myocardial Infarction And Death from Cardiovascular Causes Alternative Interpretations of the Evidence George A.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Josephine Mak Waikato Cardiothoracic Unit Journal Club
an open, prospective, randomized, multicentre trial
Total Occlusion Study of Canada (TOSCA-2) Trial
The American College of Cardiology Presented by Dr. Adnan Kastrati
The Importance of Adequately Powered Studies
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Quality of Care in Chinese Hospitals: Processes and Outcomes After ST-segment Elevation Myocardial Infarction Nicholas S. Downing, MD; Yongfei Wang, MS;
Figure 1 PCI strategies in patients with STEMI and multivessel disease
A Systematic Review and Meta-analysis of Randomized Trials of Manual Thrombectomy in ST elevation myocardial infarction Investigators: Ashraf Alazzoni,
Published in the European Heart Journal
American College of Cardiology Presented by Dr. Michel R. Le May
Global Registry of Acute Coronary Events: GRACE
Mancini JG, et al. Am J Cardiol.
China PEACE risk estimation tool for in-hospital death from acute myocardial infarction: an early risk classification tree for decisions about fibrinolytic.
Efficacy and Safety of Enoxaparin vs UFH in ST-elevation MI: A Meta-Analysis of 27,000 Patients Sabina A Murphy C Michael Gibson, David A Morrow, Carolyn.
Maintenance of Long-Term Clinical Benefit with
European Heart Journal Advance Access
National Quality Assessment of Early Clopidogrel Therapy in Chinese Patients With Acute Myocardial Infarction (AMI) in 2006 and 2011: Insights From the.
INTRO AMI. INTEGRILIN AND. REDUCED DOSE. OF THROMBOLYTIC IN. ACUTE
Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from  
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials Harindra C. Wijeysundera, MD; Ram Vijayaraghavan, MD; Brahmajee K. Nallamothu, MD, MPH; JoAnne M. Foody, MD; Harlan M. Krumholz, MD, SM; Christopher O. Phillips, MD, MPH; Amir Kashani, MD, MS; John J. You, MD; Jack V. Tu, MD, PhD; Dennis T. Ko, MD, MSc Published in the Journal of the American College of Cardiology January 30, 2007 Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials

Clinical Trial Results. org The investigators sought to best estimate the benefits and risks associated with rescue PCI and repeat fibrinolytic therapy as compared with conservative management in patients with failed fibrinolytic therapy for ST- segment myocardial infarction (STEMI).The investigators sought to best estimate the benefits and risks associated with rescue PCI and repeat fibrinolytic therapy as compared with conservative management in patients with failed fibrinolytic therapy for ST- segment myocardial infarction (STEMI). Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4): Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Background

Clinical Trial Results. org Fibrinolytic therapy is the most common treatment for STEMI; however, the best strategy to treat patients who fail to acheive reperfusion after fibrinolytic therapy remains uncertain.Fibrinolytic therapy is the most common treatment for STEMI; however, the best strategy to treat patients who fail to acheive reperfusion after fibrinolytic therapy remains uncertain. Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4): Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Background (cont.)

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Study Design  Clinical efficacy outcomes: All-cause mortality, heart failure, and reinfarction  Safety outcomes: Stroke, major bleeding, and minor bleeding  Clinical efficacy outcomes: All-cause mortality, heart failure, and reinfarction  Safety outcomes: Stroke, major bleeding, and minor bleeding 1177 patients from 8 clinical trials with follow-up duration ranging from hospital discharge to 6 months Meta-Analysis of randomized trials using fixed-effects model. There were 6 trials that randomized 908 patients to rescue PCI or conservative therapy and 3 trials that randomized 410 patients to repeat fibrinolysis or conservative therapy (REACT trial used for both analyses) patients from 8 clinical trials with follow-up duration ranging from hospital discharge to 6 months Meta-Analysis of randomized trials using fixed-effects model. There were 6 trials that randomized 908 patients to rescue PCI or conservative therapy and 3 trials that randomized 410 patients to repeat fibrinolysis or conservative therapy (REACT trial used for both analyses). Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4): Rescue PCI n=454 Conservative Treatment n=454 Follow-up ranged from hospital discharge to 6 months Follow-up ranged from hospital discharge to 6 months Repeat Fibrinolysis n=206 Conservative Treatment n=204 Follow-up ranged from hospital discharge to 6 months Follow-up ranged from hospital discharge to 6 months

Clinical Trial Results. org Rescue PCI vs Conservative Treatment p = 0.09 p = 0.05 p < Patients (%) The overall absolute reduction in the composite endpoint of all-cause mortality, heart failure, or reinfarction was substantial in the rescue-PCI group, requiring only 9 patients to be treated to yield 1 patient with benefit.The overall absolute reduction in the composite endpoint of all-cause mortality, heart failure, or reinfarction was substantial in the rescue-PCI group, requiring only 9 patients to be treated to yield 1 patient with benefit. Rescue PCI vs Conservative Treatment: Outcomes p = 0.04 Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4):

Clinical Trial Results. org Repeat Fibrinolysis vs Conservative Treatment p = 0.14 p = 0.09 p = 0.03 On the contrary, repeat fibrinolysis was not associated with significant improvements in all- cause mortality or reinfarction, and it also showed an increased risk for minor bleeding.On the contrary, repeat fibrinolysis was not associated with significant improvements in all- cause mortality or reinfarction, and it also showed an increased risk for minor bleeding. Repeat Fibrinolysis vs Conservative Treatment: Outcomes Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4): Patients (%) p = 0.42

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Limitations Despite the absence of statistically significant heterogeneity, there are substantial differences in the entrance criteria of the included trials.Despite the absence of statistically significant heterogeneity, there are substantial differences in the entrance criteria of the included trials. It is difficult to evaluate reperfusion without performing angiography, and this is a major barrier to the adoption of a standardized rescue policy for management of failed fibrinolytic therapy. It is difficult to evaluate reperfusion without performing angiography, and this is a major barrier to the adoption of a standardized rescue policy for management of failed fibrinolytic therapy. Despite the absence of statistically significant heterogeneity, there are substantial differences in the entrance criteria of the included trials.Despite the absence of statistically significant heterogeneity, there are substantial differences in the entrance criteria of the included trials. It is difficult to evaluate reperfusion without performing angiography, and this is a major barrier to the adoption of a standardized rescue policy for management of failed fibrinolytic therapy. It is difficult to evaluate reperfusion without performing angiography, and this is a major barrier to the adoption of a standardized rescue policy for management of failed fibrinolytic therapy. Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4):

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Limitations (cont.) The meta-analysis’ pooled estimates are based on <500 patients randomized per arm reflecting the difficulty in recruiting patients for trials in this area. Given the small numbers in these analyses, the ability to detect a reduction in mortality may have been underpowered (particularly in the repeat lytic arm), and likewise spuriously false positive results may emerge. The meta-analysis’ pooled estimates are based on <500 patients randomized per arm reflecting the difficulty in recruiting patients for trials in this area. Given the small numbers in these analyses, the ability to detect a reduction in mortality may have been underpowered (particularly in the repeat lytic arm), and likewise spuriously false positive results may emerge. Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4):

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Summary This meta-analysis, which systematically reviewed the existing literature of randomized trials on treatment strategies for STEMI patients who fail fibrinolytic therapy, found that rescue PCI was associated with significant risk reductions for heart failure and reinfarction. In addition, the overall absolute reduction in the composite end point of all-cause mortality, heart failure, or reinfarction was statistically significant for rescue PCI. This meta-analysis, which systematically reviewed the existing literature of randomized trials on treatment strategies for STEMI patients who fail fibrinolytic therapy, found that rescue PCI was associated with significant risk reductions for heart failure and reinfarction. In addition, the overall absolute reduction in the composite end point of all-cause mortality, heart failure, or reinfarction was statistically significant for rescue PCI. Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4):

Clinical Trial Results. org Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for STEMI: Summary (cont.) Rescue PCI was associated with an increased risk of stroke and minor bleeding and thus, the potential benefits of rescue PCI must be interpreted in the context of its risks. Few conclusions can be reached regarding repeat fibrinolysis given the small sample sizes, although more bleeding was observed with this approach. Rescue PCI was associated with an increased risk of stroke and minor bleeding and thus, the potential benefits of rescue PCI must be interpreted in the context of its risks. Few conclusions can be reached regarding repeat fibrinolysis given the small sample sizes, although more bleeding was observed with this approach. Wijeysundera HC, et al. JACC. 30 Jan 2007:49(4):